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Abstract
Background: Annual direct costs for cardiovascular (CV) diseases in the United States are approximately $195.6
billion, with many high-risk patients remaining at risk for major cardiovascular events (CVE). This study evaluated
the direct clinical and economic burden associated with new CVE up to 3 years post-event among patients with
hyperlipidemia.
Methods: Hyperlipidemic patients with a primary inpatient claim for new CVE (myocardial infarction, unstable
angina, ischemic stroke, transient ischemic attack, coronary artery bypass graft, percutaneous coronary intervention and
heart failure) were identified using IMS LifeLink PharMetrics Plus data from January 1, 2006 through June 30, 2012.
Patients were stratified by CV risk into history of CVE, modified coronary heart disease risk equivalent, moderate- and
low-risk cohorts. Of the eligible patients, propensity score matched 243,640 patients with or without new CVE were
included to compare healthcare resource utilization and direct costs ranging from the acute (1-month) phase through
3 years post-CVE date (follow-up period).
Results: Myocardial infarction was the most common CVE in all the risk cohorts. During the acute phase, among
patients with new CVE, the average incremental inpatient length of stay and incremental costs ranged from
4.4–6.2 days and $25,666–$30,321, respectively. Acute-phase incremental costs accounted for 61–75 % of first-year
costs, but incremental costs also remained high during years 2 and 3 post-CVE.
Conclusions: Among hyperlipidemic patients with new CVE, healthcare utilization and costs incurred were
significantly higher than for those without CVE during the acute phase, and remained higher up to 3 years post-event,
across all risk cohorts.
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Background
The global cost of cardiovascular disease (CVD) is esti-
mated at $ 863 billion and is estimated to rise to $ 1,044
billion in 2030 [1]. The American Heart Association has
estimated the direct costs for CVD in the United States at
$195.6 billion, approximately 61 % of the total CVD-
related healthcare costs [2]. Additionally, hyperlipidemia
was among the top 10 costliest medical conditions in
2008 in the US adult population [3]. Presence of hyper-
lipidemia directly correlates with the risk of developing
coronary heart disease (CHD) and future cardiovascular
(CV) events [4]. Less than half of adults with elevated
low density lipoprotein cholesterol (LDL-C) levels re-
ceive treatment or are adequately treated [5, 6] and as a
result, high-risk patients continue to remain at risk for
new CV events. Almost 44 % of the US population is
projected to be diagnosed with some form of CVD by
2030 [2]. These factors result in a substantial clinical
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and economic burden in terms of direct healthcare
utilization and costs.
While several studies have examined the economic bur-
den of CV events [7–12], to our knowledge contemporary
and long-term analyses concerning these event costs
incurred by hyperlipidemic patients across a range of
CVD risk levels is not available. Previous studies focused
on short-term healthcare costs due to CV events [13–17]
and investigated patient populations diagnosed with acute
coronary syndrome [13, 14], hypertension [15], athero-
sclerosis [16] or diabetes [17], but not hyperlipidemia.
Furthermore, prior studies focused only on the initial CV
event and therefore, limited data are available regarding re-
current and subsequent CV event costs. Prior studies have
investigated the economic burden of CV events over vari-
ous time periods [10]; however, incremental costs among
hyperlipidemic patients with and without CV events, and
in particular, costs stratified by CVD risk level and associ-
ated with myocardial infarction (MI), ischemic stroke (IS)
unstable angina (UA), coronary artery bypass graft (CABG),
percutaneous coronary intervention (PCI), heart failure
(HF) and transient ischemic attack (TIA), all in one study,
have not been previously examined. Therefore, the present
study is one of the first to estimate the short-term and
long-term (up to 3 years) direct clinical and economic bur-
den of new CV events among hyperlipidemic patients at
different CVD risk levels and by specific CV event type.
Methods
Study design
We conducted a retrospective cohort study including
patients with a hyperlipidemia diagnosis who had a new
CV event matched to patients without new CV events,
using the IMS LifeLink PharMetrics Plus dataset for the
study period January 1, 2006 through June 30, 2012. This
nationally-representative longitudinal database contains
medical and pharmacy claims for over 50 million
commercially-insured patients throughout the United
States [7, 18, 19]. All claims data were from a limited data-
set with de-identified patient information. No patients
were directly involved in the study; therefore, this study
was exempt from an Institutional Review Board review.
Study population
Patients (age ≥18) were included in the study if they
had ≥1 medical claims for hyperlipidemia (International
Classification of Diseases, 9th Revision Clinical Modifica-
tions [ICD-9-CM] code 272) [20] from January 1, 2006
through June 30, 2009. The first diagnosis claim date was
designated as the hyperlipidemia diagnosis date. As
detailed in Appendix 1, patients were required to have at
least one inpatient medical claim for a new CV event (MI,
IS, UA, TIA, HF, CABG and PCI) after the hyperlipidemia
diagnosis date and during the identification period
(January 1, 2007 through June 30, 2009). For hyperlip-
idemic patients with a new CV event, the earliest inpatient
claim date was designated as the index date. If a patient
had more than one inpatient claim for a new CV event on
the index date, only one CV event was selected, according
to the following hierarchy: MI, IS, UA, HF, TIA, CABG
and then PCI, based on the clinical importance (e.g.
acute/urgency) of CV events and CV-related procedures.
The comparison group included patients with no new CV
event after the hyperlipidemia diagnosis and through the
end of the study period (June 30, 2012). Baseline period of
the 12 months prior to the index date was utilized to
characterize patients’ CV risk level (e.g. history of CVE or
diabetes) and comorbidity status. Patients were followed
from the index date through 3 years post-index date to
estimate short-term (first 30 days and 1 year) and longer-
term (2 years and 3 years) direct costs.
Matching was completed in a two-step approach. The
first step was 1:1 match (age, gender, US region) to assign
an index date for patients without a new CV event and de-
fine the baseline period for quantifying baseline characteris-
tics (CV risk level, comorbidities). These initially matched
patients with no new CV event were then assigned the
same index date as that of their matched patients who had
a new CV event. This assignment of index date to patients
with no new CV event provided the same baseline and
follow-up time periods for the comparison of outcomes be-
tween patients with and without new CV events.
The second step of matching, propensity score matching
(PSM) with 0.01 calipers, was applied to control the
differences in baseline clinical and demographic factors
between patients with and without new CV events within
each risk cohort [21, 22]. A standardized difference (STD)
of >10 % was used to assess significant practical differ-
ences in the case–control comparison [23]. The baseline
variables adjusted in the model were age group, gender,
US region, Charlson comorbidity index (CCI) score,
Chronic Disease Score (CDS), individual comorbid condi-
tions (hypertension, arrhythmias, metabolic syndrome,
liver disease, obesity, and chronic kidney disease) and
number of inpatient admissions per patient per month
(PPPM). The methods used in this study have also been
published in prior literature [7, 10]. The CCI score is based
on ICD-9 codes and CDS uses pharmacy dispensation in-
formation for specific drug classes to estimate the burden
of comorbidities [24]. The CCI and CDS score have been
widely used in many retrospective studies [25–28].
Based on the risk level during the 12-month pre-index
(baseline period), the study sample was subdivided into
the following CVD risk cohorts: history of CV event,
modified CHD risk equivalent (RE), moderate risk and
low risk (Fig. 1). Risk levels were defined based on the
National Cholesterol Education Program (NCEP) Adult
Treatment Panel (ATP) III guidelines [29] (Appendix 2).
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The history of CV event cohort included patients with
MI, UA, CABG, PCI or IS, the modified CHD RE cohort
included patients with peripheral arterial disease, abdom-
inal aortic aneurysm, coronary artery disease, diabetes or
dyslipidemia. Patients with at least two of the following
three risk factors a) hypertension and/or pharmacy claim
for blood pressure-lowering medication, b) aged ≥45 for
men and aged ≥55 for women, c) pre-index high-density
lipoprotein cholesterol <40 mg/dl were included in the
moderate risk cohort, and patients with zero or one risk
factor were included in the low risk cohort [see Appendix 2
for detailed ICD-9-CM codes]. Outcome measures in-
cluded distribution of CV event type, healthcare utilization,
and direct incremental costs (obtained from claims) in-
curred during the acute (first 1 month post-index date),
and long-term (1, 2, 3 years post-index date) follow-up pe-
riods for hyperlipidemia patients, stratified by CVD risk
level. Healthcare utilization included inpatient, outpatient,
outpatient office, emergency room and pharmacy visits and
direct costs associated with healthcare utilization were
computed from health plan- and patient-paid amounts.
Total costs included inpatient, outpatient and pharmacy
costs. Costs were adjusted to 2012 US dollars using the an-
nual medical care component of the consumer price index
(CPI) to reflect inflation.
Statistical analysis
Descriptive analysis
Descriptive analysis was conducted to compare demographic
and clinical characteristics between patients with and with-
out a new CV event within each risk cohort. The direct total
incremental costs were calculated as the difference in total
costs for patients with a new CV event and total costs for
patients without a CV event. Negative incremental costs
indicate that the total costs were lower for patients with
new CV events than for patients without new CV events.
Multivariate analysis
The differences in economic outcomes for each risk cohort
were compared among PSM cases and controls. Patients
Fig. 1 Patient Selection Flowchart. *Propensity score matching was applied for each cardiovascular disease risk cohort using covariates: age group,
gender, US region, baseline Charlson comorbidity index score, Chronic Disease Score, comorbidities and number of inpatient admissions per patient
per month. CV: cardiovascular; CHD RE: coronary heart disease risk equivalent; PSM: propensity score matching
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without new CV events were designated as the reference
group (controls). All analyses were performed using SAS®
version 9.3 (SAS® Institute Inc., Cary, NC).
Results
Among patients with a new CV event, a large propor-
tion had two or more new CV events (65.8 %) during
the 3-year follow-up period. Second and subsequent
CV events during follow-up were often the same
event type as the first event. A total of 451,450
patients were eligible for the study, among which
267,165 patients had a new CV event, and 184,285
patients had no new CV event before 1:1 matching. A
total of 184,285 hyperlipidemic patients with new CV
events from January 1, 2006 through June 30, 2009
were matched according to age, gender and US
region to 184,285 hyperlipidemic patients without a
new CV event (Fig. 1).
Baseline demographic and clinical characteristics
Baseline demographic and characteristics of un-
matched patients with a new CV event (N = 267,165)
and patients without a new CV event (N = 184,285)
are provided in Appendix 3. Baseline demographic
and clinical characteristics for propensity score-
matched patients with a new CV event (N = 121,820)
and patients without a new CV event (N = 121,820),
stratified by CVD risk level, are provided in Table 1.
Patients without CV events were well-matched with
patients with new CV event within each risk cohort,
since the STD was <10 % for all variables included in
the PSM. The majority of patients were classified in
the modified CHD RE cohort (74.4 %), followed by the
history of CV event cohort (8.8 %). Overall, the average
age of patients with a new CV event (N = 121,820)
ranged from 56 to 72 years; 65–67 % were male; and
hypertension was the most common baseline comor-
bidity (4.7–84.4 %).
Clinical burden
MI was more commonly diagnosed than other CV event
types among patients in the low-risk, moderate-risk and
modified CHD RE cohorts. Frequency of MI, IS and HF
was similar among patients in the history of CV event
cohort (Fig. 2).
During the 1 month post-index date, among patients
with history of a CV event (n = 10,741), the mean
inpatient length of stay (LOS) was significantly longer
among hyperlipidemic patients with a new CV event
compared to those without (6.4 vs. 0.25 days, p < 0.0001,
Table 2). This trend was observed across all risk cohorts.
The inpatient LOS remained longer during the short-
and long-term follow-up periods among patients with a
new CV event, compared to those without, for all risk
cohorts (e.g. history of CV event cohort inpatient LOS
in year 2 = 4.14 vs. 1.50 days, p < 0.0001, and in year 3 =
3.72 vs. 1.38 days, p < 0.0001) (Table 3).
During the 1 month post-index date, patients with
history of a CV event (n = 10,741) had significantly
more outpatient emergency room (ER) visits PPPM
compared to patients without a new CV event (0.17
vs. 0.04 visits, p < 0.0001, Table 2). This trend contin-
ued across all risk cohorts and during all follow-up
periods (Tables 2 & 3). Among hyperlipidemic pa-
tients with new CV events, all resource utilization
components were highest during the 1-month post-
index follow-up phase for all risk cohorts, indicating
that the highest healthcare utilization occurred during
the first month post-CV event. However, healthcare
resource utilization during years 2 and 3 of the
follow-up period remained significantly higher for
patients with a new CV event than for those without,
across all risk cohorts (e.g. history of CV event
cohort ER visits PPPM during year 2 =0.05 vs. 0.03 visits,
p < 0.0001; and year 3 = 0.05 vs. 0.03 visits, p < 0.0001).
Economic burden
Across all CV event type and risk cohorts, the direct
incremental costs ranged from $17,903 to $65,825 in the
first year of follow-up period, $474 to $19,617 during
the second year post-CV event and $2,598 to $26,982
during the third year post-CV event (Table 4).
Direct incremental costs categorized by CV event type
varied in relation to the duration of the follow-up
period. The direct incremental costs accrued during the
1-month post-index phase represented approximately
45-90 % of first-year costs (data not shown). During the
first year post-CV event, CABG costs were highest
($55,548–$65,825) for all risk cohorts, followed by MI
($47,840–$51,686) and HF ($41,001–$46,890). During
years 2 and 3 post-index date, patients diagnosed with
HF incurred the highest cost burden (year 2:
$11,289–$19,617; year 3: $7,820–$26,982) among all risk
cohorts. The direct incremental costs during these years
were mainly driven by heart failure. For all CV event
types, first-year incremental costs were higher compared
to those accrued in the second and third post-CV event
years; second- and third-year costs were always higher
for hyperlipidemic patients with new CV events than for
their matched patients without CV events.
Discussion
Our study showed that the long-term clinical and
economic burden associated with CV events among
hyperlipidemic patients was substantial across all risk
cohorts, but especially among high-risk cohorts (i.e.
patients with history of a CV event and prior CHD
RE diagnosis). Our mean healthcare resource
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Table 1 PSM-adjusted 12-month pre-index demographic and clinical characteristics for hyperlipidemic patients with and without new CV events

































Age 73.66(13.15) 71.76(12.18) <0.0001 65.32(12.95) 64.69(12.75) <0.0001 65.58(11.93) 65.45(12.11) 0.503 56.18(11.24) 55.86(10.92) 0.022
18–24 [0.0 %] [0.0 %] N/A 0.0 [0.0 %] [0.0 %] 0.336 0.5 [0.0 %] [0.0 %] N/A 0.0 [0.1 %] [0.1 %] 0.683 0.5
25–34 [0.1 %] [0.1 %] 0.781 0.4 [0.3 %] [0.3 %] 0.189 0.6 [0.0 %] [0.0 %] N/A 0.0 [1.1 %] [1.1 %] 0.952 0.1
35–54 [7.0 %] [6.0 %] 0.006 3.8 [19.0 %] [19.7 %] <0.0001 1.9 [14.6 %] [14.5 %] 0.946 0.1 [45.6 %] [45.6 %] 0.970 0.1
55–64 [22.1 %] [20.9 %] 0.043 2.8 [36.7 %] [36.4 %] 0.1 0.8 [43.9 %] [43.8 %] 0.949 0.1 [36.9 %] [36.9 %] 0.990 0.0
≥65 [70.9 %] [73.0 %] 0.001 4.6 [44.0 %] [43.6 %] 0.129 0.7 [41.6 %] [41.7 %] 0.910 0.2 [16.3 %] [16.3 %] 0.932 0.1
Male [66.6 %] [65.2 %] 0.029 3.0 [65.3 %] [65.2 %] 0.657 0.2 [66.7 %] [66.7 %] 0.946 0.1 [64.7 %] [64.7 %] 0.926 0.1
US geographic region
Northeast [39.3 %] [39.5 %] 0.769 0.4 [35.5 %] [35.3 %] 0.366 0.4 [32.1 %] [32.1 %] 0.973 0.1 [35.2 %] [35.3 %] 0.874 0.2
Midwest [22.1 %] [23.3 %] 0.040 2.8 [25.9 %] [26.0 %] 0.351 0.4 [28.2 %] [28.3 %] 0.930 0.1 [26.5 %] [26.5 %] 0.989 0.0
South [24.4 %] [22.6 %] 0.002 4.3 [27.6 %] [27.6 %] 0.992 0.0 [28.3 %] [28.1 %] 0.874 0.3 [28.9 %] [28.8 %] 0.933 0.1
West [14.2 %] [14.7 %] 0.351 1.3 [11.1 %] [11.1 %] 0.929 0.0 [11.4 %] [11.5 %] 0.960 0.1 [9.4 %] [9.3 %] 0.914 0.1
Baseline comorbid
condition
CCI Score 2.72(2.15) 2.82(2.14) <0.001 4.9 1.23(1.54) 1.21(1.47) <0.001 1.7 0.32(0.77) 0.31(0.75) 0.876 0.3 0.14(0.5) 0.14(0.49) 0.848 0.2
Chronic disease
score
5.29(4.06) 5.49(4.19) <0.001 5.0 4.58(3.62) 4.57(3.65) 0.716 0.2 3.99(2.86) 3.99(2.87) 0.892 0.2 0.97(1.74) 0.97(1.74) 0.957 0.1
Baseline number of
inpatient visits PPPM
0.19(0.49) 0.2(0.45) 0.193 1.8 0.04(0.19) 0.04(018) 0.007 1.3 0.01(0.05) 0.01(0.05) 0.817 0.4 0(0.03) 0(0.03) 0.654 0.6
Propensity score matching was applied for each cardiovascular disease risk cohort using covariates: age group, gender, US region, baseline Charlson comorbidity index score, Chronic Disease Score, comorbidities
(hypertension, arrhythmias, metabolic syndrome, liver disease, obesity and chronic kidney disease) and number of inpatient admissions per patient per month.
CHD RE coronary heart disease risk equivalent, SD standard deviation, STD standardized difference, CV cardiovascular, CVD cardiovascular disease, PPPM per patient per month, PSM propensity score matching













utilization analysis demonstrated that during the
acute follow-up period, hyperlipidemic patients with
new CV events had an additional +4.4 to +6.2 (days)
inpatient LOS and +2.6 to +3.6 outpatient visits
PPPM, compared to patients without CV events. The
clinical burden remained over the long-term, and
was substantial for patients with a new CV event
(year 2 incremental inpatient LOS: +0.5 to +2.6, out-
patient visits PPPM: +0.2 to +0.3; year 3 incremental
inpatient LOS: +0.4 to +2.3, outpatient visits PPPM:
+0.1 to +0.3). The pattern of long term healthcare
resource utilization among patients with new CV
events may be attributable to the higher long term
HF costs. Our study also reported that a large pro-
portion (65.8 %) of patients with a new CV event
had more than one new CV event during the follow-
up period, adding to the long-term clinical burden
of CV events on hyperlipidemic patients. These are
only the direct medical costs of care; total costs
would be larger if other indirect costs associated
with CVE were accounted for. A prior study did
show that new CVE were associated with increased
indirect costs [30].
Previous studies have reported that inpatient hos-
pital stays and ER visits are expensive, resource inten-
sive and impose a great clinical burden on patients
[31, 32]. Higher healthcare resource utilization is a
major component of increased healthcare costs.
Healthcare costs were higher among hyperlipidemic
patients with a new CV event in the acute phase,
compared to patients without a new CV event. Our re-
sults are similar to the Chapman et al. study, which con-
cluded that patients with new CV events incurred the
highest follow-up costs during the acute phase, and acute
phase costs were much higher than those in years 2 and 3
[7]. However, our study also determined that incremental
costs remained higher through 3 years of follow-up (year
1: $39,869 to $41,648 higher; year 2: $5,900 to $ 9,436
higher; year 3: $4,704 to $11,400 higher), for all risk co-
horts of hyperlipidemic patients with a new CV event,
compared to those without, emphasizing a sustained
economic burden. Compared with the Chapman et al.
[7] study with cost estimates from 2001–2006, the
present study also provides more recent estimates for
healthcare resource utilization and costs across the
CVD risk spectrum (history of CV events through
low risk) rather than excluding the highest risk cohort
(i.e. patients with a history of CV events) as in the Chap-
man et al. study. Our study also captures the cost of care
for multiple CV events thereby providing a more accurate
estimate of the direct cost of care for patients experiencing
new CV events rather than estimating the cost for each
Fig. 2 PSM-adjusted Distribution of Index CV Event According to CVD Risk Level. CV: cardiovascular; CVD: cardiovascular disease; PSM: propensity
score matching; MI: myocardial infarction; UA: unstable angina; IS: ischemic stroke; CABG: coronary artery bypass graft; PCI: percutaneous coronary
intervention; HF: heart failure; TIA: transient ischemic attack; CHD RE: coronary heart disease risk equivalent
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Table 2 PSM-adjusted follow-up (short and long-term) healthcare utilization for hyperlipidemic patients with and without new CV events, categorized by CVD risk level



































All-cause healthcare utilization 1 month (acute phase) post-index date
Number of continuous
enrollment patients
10577[98.5 %] 10282[95.7 %] <0.0001 89539[98.8 %] 88196[97.3 %] <0.0001 7845[98.8 %] 7727[97.3 %] <0.0001 12428[99.2 %] 12317[98.3 %] <0.0001
Inpatient LOS (days) 0.25(1.94) 6.43(6.94) <0.0001 0.07(0.90) 5.22(5.39) <0.0001 0.04(0.61) 4.97(4.91) <0.0001 0.01(0.35) 4.42(4.08) <0.0001
Number of patients with
Inpatient Visits
346[3.3 %] 10282[100.0 %] <0.0001 1102[1.2 %] 88196[100.0 %] <0.0001 59[0.8 %] 7727[100.0 %] <0.0001 32[0 .3 %] 12317[100.0 %] <0.0001
Number of patients with
Outpatient ER Visits
387[3.7 %] 1503[14.6 %] <0.0001 1674[1.9 %] 15425[17.5 %] <0.0001 124[1.6 %] 1663[21.5 %] <0.0001 128[1.0 %] 3194[25.9 %] <0.0001
Number of patients with
Outpatient Office Visits
5431[51.3 %] 7141[69.5 %] <0.0001 39190[43.8 %] 67063[76.0 %] <0.0001 2857[36.4 %] 5654[73.2 %] <0.0001 3110[25.0 %] 9311[75.6 %] <0.0001
Number of patients with
Outpatient Visitsb
7297[69.0 %] 9296[90.4 %] <0.0001 50185[56.0 %] 81329[92.2 %] <0.0001 3616[46.1 %] 7078[91.6 %] <0.0001 3895[31.3 %] 11266[91.5 %] <0.0001
Number of patients with
Outpatient Pharmacy Visits
6842[64.7 %] 7253[70.5 %] <0.0001 56480[63.1 %] 67216[76.2 %] <0.0001 4736[60.4 %] 6266[81.1 %] <0.0001 3500[28.2 %] 9242[75.0 %] <0.0001
Number of visits (PPPM)
Inpatient stays 0.04(0.21) 1.18 (0.48) <0.0001 0.01(0.13) 1.14(0.42) <0.0001 0.01(0.11) 1.13(0.40) <0.0001 0.00(0.06) 1.11(0.36) <0.0001
Outpatient Visitsb 2.06(2.76) 4.64(4.68) <0.0001 1.35(2.05) 4.29(4.11) <0.0001 1.00(1.67) 4.17(4.08) <0.0001 0.64(1.32) 4.24(4.13) <0.0001
Outpatient ER Visits 0.04(0.22) 0.17(0.45) <0.0001 0.02(0.16) 0.20(0.47) <0.0001 0.02(0.14) 0.25(0.51) <0.0001 0.01(0.12) 0.29(0.53) <0.0001
Outpatient Pharmacy Visits 1.76(1.93) 2.29(2.16) <0.0001 1.43(1.60) 2.34(1.96) <0.0001 1.21(1.40) 2.28(1.76) <0.0001 0.47(0.93) 1.74(1.50) <0.0001
Outpatient Office Visits 1.00(1.50) 1.42(1.49) <0.0001 0.77(1.31) 1.50(1.41) <0.0001 0.62(1.19) 1.38(1.35) <.0001 0.41(0.98) 1.39(1.34) <0.0001
All-cause Healthcare Utilizations 1 year (31–365 days) post-index date
Number of continuous
enrollment patients
8447[78.6 %] 7808[72.7 %] <0.0001 75203[83.0 %] 70525[77.8 %] <0.0001 6588[83.0 %] 6165[77.7 %] <.0001 10806[86.3 %] 10089[80.5 %] <0.0001
Inpatient LOS (days) 2.06(13.01) 6.61(20.85) <0.0001 0.70(4.94) 3.20(13.27) <0.0001 0.51(3.98) 2.46(11.26) <.0001 0.23(2.72) 1.75(10.73) <0.0001
Number of patients with
Inpatient Visits
1304[15.4 %] 2916[37.3 %] <0.0001 6442[8.6 %] 18316[26.0 %] <0.0001 445[6.8 %] 1439[23.3 %] <.0001 376[3.5 %] 1747[17.3 %] <0.0001
Number of patients with
Outpatient ER Visits
2062[24.4 %] 2767[35.4 %] <0.0001 11284[15.0 %] 19597[27.8 %] <0.0001 876[13.3 %] 1558[25.3 %] <.0001 1109[10.3 %] 2370[23.5 %] <0.0001
Number of patients with
Outpatient Office Visits
7810[92.5 %] 7423[95.1 %] <0.0001 70005[93.1 %] 68022[96.5 %] <0.0001 5692[86.4 %] 5801[94.1 %] <.0001 8009[74.1 %] 9396[93.1 %] <0.0001
Number of patients with
Outpatient Visitsb













Table 2 PSM-adjusted follow-up (short and long-term) healthcare utilization for hyperlipidemic patients with and without new CV events, categorized by CVD risk level
(Continued)
Number of patients with
Outpatient Pharmacy Visits
6685[79.1 %] 6397[81.9 %] <0.0001 61668[82.0 %] 59379[84.2 %] <0.0001 5440[82.6 %] 5411[87.8 %] <.0001 6611[61.2 %] 8281[82.1 %] <0.0001
Number of visits PPPM
Inpatient stays 0.02(0.06) 0.06(0.11) <0.0001 0.01(0.04) 0.04(0.09) <0.0001 0.01(0.03) 0.03(0.07) <.0001 0.00(0.02) 0.02(0.06) <0.0001
OutpatientVisitsb 1.81(1.71) 2.62(2.20) <0.0001 1.28(1.33) 2.13(1.86) <0.0001 0.95(1.09) 1.74(1.62) <.0001 0.65(0.88) 1.50(1.47) <0.0001
Outpatient ER Visits 0.04(0.08) 0.06(0.14) <0.0001 0.02(0.06) 0.04(0.10) <0.0001 0.02(0.05) 0.04(0.09) <.0001 0.01(0.04) 0.03(0.08) <0.0001
Outpatient Pharmacy Visits 1.66(1.53) 2.05(1.69) <0.0001 1.37(1.28) 1.87(1.48) <0.0001 1.18(1.12) 1.80(1.32) <.0001 0.50(0.75) 1.29(1.11) <0.0001
Outpatient Office Visits 0.90(0.88) 1.10(0.99) <0.0001 0.73(0.79) 0.98(0.87) <0.0001 0.57(0.71) 0.80(0.80) <0.0001 0.42(0.64) 0.68(0.73) <0.0001
All-cause healthcare utilization 2 years post-index date
Number of patients with
Inpatient Visits
848[14.3 %] 1660[29.8 %] <0.0001 5208[8.8 %] 11020[20.7 %] <0.0001 394[7.7 %] 856[18.4 %] <0.0001 391[4.4 %] 915[11.7 %] <0.0001
Number of patients with
Outpatient ER Visits
1455[24.5 %] 1845[33.1 %] <0.0001 9514[16.1 %] 13799[25.9 %] <0.0001 759[14.9 %] 1134[24.3 %] <0.0001 963[10.9 %] 1583[20.2 %] <0.0001
Number of patients with
Outpatient Office Visits
5371[90.6 %] 5084[91.2 %] 0.286 54074[91.8 %] 49751[93.5 %] <0.0001 4433[87.0 %] 4213[90.4 %] <0.0001 6969[78.8 %] 6944[88.8 %] <0.0001
Number of patients with
Outpatient Visitsb
5668[95.6 %] 5352[96.0 %] 0.325 55882[94.9 %] 51394[96.6 %] <0.0001 4669[91.6 %] 4445[95.3 %] <0.0001 7377[83.4 %] 7286[93.1 %] <0.0001
Number of patients with
Outpatient Pharmacy Visits
4720[79.6 %] 4549[81.6 %] 0.008 48323[82.0 %] 44590[83.8 %] <0.0001 4228[83.0 %] 4015[86.1 %] <0.0001 5886[66.6 %] 6324[80.8 %] <0.0001
All-cause healthcare utilization 3 years post-index date
Number of patients with
Inpatient Visits
563[14.1 %] 961[27.2 %] <0.0001 3941[8.8 %] 7146[18.6 %] <0.0001 288[7.4 %] 590[16.9 %] <0.0001 325[4.5 %] 617[10.3 %] <0.0001
Number of patients with
Outpatient ER Visits
965[24.2 %] 1173[33.2 %] <0.0001 7049[15.8 %] 9683[25.2 %] <0.0001 503[12.9 %] 817[23.4 %] <0.0001 804[11.2 %] 1187[19.9 %] <0.0001
Number of patients with
Outpatient Office Visits
3569[89.4 %] 3150[89.2 %] 0.78 40638[91.0 %] 35419[92.0 %] <0.0001 3420[87.6 %] 3095[88.8 %] 0.115 5871[81.7 %] 5209[87.2 %] <0.0001
Number of patients with
Outpatient Visitsb
3775[94.5 %] 3335[94.4 %] 0.819 42139[94.4 %] 36762[95.5 %] <0.0001 3587[91.9 %] 3272[93.9 %] 0.001 6194[86.2 %] 5468[91.6 %] <0.0001
Number of patients with
Outpatient Pharmacy Visits
3216[80.5 %] 2908[82.3 %] 0.047 36437[81.6 %] 32319[84.0 %] <0.0001 3221[82.5 %] 2958[84.9 %] 0.006 4991[69.4 %] 4804[80.5 %] <0.0001
Refer to Table 3 for length of stay and number of visits per patient per month during years 2 and 3 of the follow-up period
PSM propensity score matching, CVD cardiovascular disease, CV cardiovascular, CHD RE coronary heart disease risk equivalent, SD standard deviation, LOS length of stay, PPPM per patient per month, ER emergency room
aChi-square tests were used to evaluate the statistical significance of differences in categorical variables; student t-tests were used for the continuous variables













Table 3 PSM-adjusted follow-up (2 years and 3 years) healthcare utilization for hyperlipidemic patients with and without new CV events, categorized by CVD risk level



































All-cause Healthcare Utilization 2 Years Post-index Date
Number of Continuous Enrollment Patients 5928[55.2 %] 5576[51.9 %] <0.0001 58916[65.0 %] 53212[58.7 %] <0.0001 5096[64.2 %] 4662[58.7 %] <0.0001 8844[70.6 %] 7822[62.4 %] <0.0001
Inpatient LOS (days) 1.50(7.21) 4.14(16.22) <0.0001 0.71(4.81) 2.10(9.46) <0.0001 0.60(4.09) 1.78(9.78) <0.0001 0.24(1.70) 0.76(4.36) <0.0001
Number of Visits (PPPM)
Inpatient stays 0.02(0.05) 0.04(0.09) <0.0001 0.01(0.04) 0.03(0.07) <0.0001 0.01(0.03) 0.02(0.06) <0.0001 0.00(0.02) 0.01(0.04) <0.0001
Outpatient Visitsb 1.72(1.70) 2.07(2.01) <0.0001 1.26(1.36) 1.63(1.65) <0.0001 0.97(1.09) 1.27(1.31) <0.0001 0.73(0.95) 0.97(1.13) <0.0001
Outpatient ER Visits 0.03(0.08) 0.05(0.13) <0.0001 0.02(0.06) 0.04(0.09) <0.0001 0.02(0.05) 0.03(0.08) <0.0001 0.01(0.04) 0.02(0.07) <0.0001
Outpatient Pharmacy Visits 1.63(1.52) 1.96(1.70) <0.0001 1.36(1.28) 1.78(1.49) <0.0001 1.22(1.15) 1.67(1.34) <0.0001 0.62(0.87) 1.22(1.14) <0.0001
Outpatient Office Visits 0.86(0.86) 0.94(0.94) <0.0001 0.71(0.78) 0.83(0.82) <0.0001 0.56(0.67) 0.67(0.74) <0.0001 0.46(0.67) 0.53(0.64) <0.0001
All-cause Healthcare Utilization 3 Years Post-index Date
Number of Continuous Enrollment Patients 3994[37.2 %] 3533[32.9 %] <0.0001 44654[49.3 %] 38489[42.5 %] <0.0001 3903[49.2 %] 3485[43.9 %] <0.0001 7188[57.4 %] 5971[47.7 %] <0.0001
Inpatient LOS (days) 1.38(7.05) 3.72(14.25) <0.0001 0.69(4.98) 1.77(8.28) <0.0001 0.72(5.43) 1.68(8.17) <0.0001 0.29(2.57) 0.72(5.57) <0.0001
Number of visits (PPPM)
Inpatient Stays 0.02(0.05) 0.04(0.09) <0.0001 0.01(0.04) 0.02(0.07) <0.0001 0.01(0.03) 0.02(0.07) <0.0001 0.00(0.02) 0.01(0.04) <0.0001
OutpatientVisitsb 1.64(1.74) 1.97(2.14) <0.0001 1.24(1.41) 1.55(1.65) <0.0001 0.96(1.18) 1.22(1.35) <0.0001 0.77(0.97) 0.91(1.16) <0.0001
Outpatient ER Visits 0.03(0.08) 0.05(0.11) <0.0001 0.02(0.05) 0.03(0.10) <0.0001 0.01(0.04) 0.03(0.09) <0.0001 0.01(0.04) 0.02(0.06) <0.0001
Outpatient Pharmacy Visits 1.62(1.49) 1.94(1.70) <0.0001 1.36(1.29) 1.75(1.49) <0.0001 1.22(1.15) 1.60(1.31) <0.0001 0.69(0.91) 1.20(1.15) <0.0001
Outpatient Office Visits 0.83(0.86) 0.87(0.89) 0.043 0.70(0.78) 0.79(0.81) <0.0001 0.55(0.66) 0.65(0.75) <0.0001 0.48(0.69) 0.51(0.63) 0.012
PSM propensity score matching, CVD cardiovascular disease, CV cardiovascular, CHD RE coronary heart disease risk equivalent, SD standard deviation, LOS length of stay, PPPM per patient per month, ER emergency room
aChi-square tests were used to evaluate the statistical significance of differences in categorical variables; student t-tests were used for the continuous variables













Table 4 Total annual incremental costs for hyperlipidemic patients with new CV events categorized by post-event periods
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CI Confidence interval, CV cardiovascular, CHD RE coronary heart disease risk equivalent, MI myocardial infarction, IS ischemic stroke, UA unstable angina, PCI percutaneous coronary intervention, CABG coronary artery













specific CV event type. Setting potentially arbitrary time
cut-points to distinguish between different CV events
among patients with multiple events may produce artifi-
cial cost results, as some CV events may occur with little
time gap and the cost of one event is entwined with the
cost of the next event.
Our study also brings to light the noteworthy clin-
ical and economic burden among patients in the
high-risk cohorts (i.e., history of CV event and
modified CHD RE cohorts). Inpatient LOS was, on
average, 0.09 to 4.89 days longer among patients
with history of a CV event or modified CHD RE,
compared to those at moderate or lower risk, during
all follow-up time periods, suggesting that high-risk
patients have greater healthcare resource needs. Dur-
ing the long-term post-CV event periods (1, 2 and
3 years follow-up), patients with a new CV event in
the higher risk cohorts utilized more incremental ER visits
PPPM, compared to those in the moderate- and low-risk
cohorts, demonstrating the potential for a higher health-
care cost burden during the longer-term post-CV event
periods. Future research is warranted to more specifically
determine the underlying reasons for the sustained differ-
ence in clinical and economic burden between high-risk
hyperlipidemic patients with a CV event and those with-
out a CV event.
Our study results were similar to a study done by
Karan et al., indicating similarity in findings that CVD
had more outpatient and inpatients stays and economic
burden of CVD is large [33]. However, this study utilized
a national survey of households in India and focused on
out-of-pocket spending and non-medical spending for
CVD, whereas our present study focused on a patient-
level perspective of direct medical costs for new CV
events. Although previous studies provide a general
frame of reference, the cost estimates are not directly
comparable to the incremental direct costs in the
present study since the studies differed in study design
(matched cohorts versus survey sample) [34] and
composition of the study population (US hyperlipidemia
patients versus hypertension or solely acute coronary
syndrome patients including those residing in devel-
oping countries) [33, 34], sample size (n = 10,741 vs.
4,669) [10], CVD risk level (low through high CV risk
vs. exclusion of high secondary prevention patients)
[7, 8] and contemporaneous cost estimates (2009–2013
vs. 2001–2006) [7]. Due to considerable variation in costs
by CV event type, the results of our analysis strengthen
the importance of evaluating total and individual CV
event costs, as this specific information may be essential
for secondary prevention and treatment decisions for
high-risk patients.
Our present study demonstrated the sustained high
economic and clinical burden associated with the
occurrence of CV events among hyperlipidemic
patients. In patients who have already experienced or
who are at high risk for experiencing a CV event,
lifestyle intervention strategies alone may not be
sufficient to maximally reduce CVD risk [35, 36].
Current US treatment guidelines recommend lipid-
lowering therapy in addition to lifestyle modifications
to lower LDL-C levels for primary and secondary
prevention for high-risk individuals [37]. Although
statins are widely prescribed for elevated LDL-C
levels, 9 %–20 % of treated patients, especially high-
risk patients, continue to have elevated LDL-C and
remain at risk for new CV events [38]. Potential new
pharmacological treatments (e.g. anti-proprotein con-
vertase subtilisin/kexin type 9 [PCSK9] monoclonal
antibodies) aimed at significantly lowering LDL-C
beyond that of current available treatment options
[39], could potentially help to reduce the substantial
clinical and economic burden.
Limitations
Our study limitations were primarily related to the
retrospective use of claims data [7, 15]. Misclassifica-
tion of CV risk, although it cannot be quantified, is
likely to be low since the ICD-9-CM codes utilized
to capture history of CVD included codes for old
MI, stroke sequelae, etc. that would include a history
of CVD beyond the baseline period. Similarly, im-
portant patient information, including blood pres-
sure, smoking history and family history was not
available in the claims data to more accurately
classify patients within the CHD RE cohort. Also,
administrative claims data do not offer information
on whether an elective procedure (CABG, PCI) was
planned, thus planned procedures could not be com-
pletely excluded from the study. Nevertheless,
utilization of the PSM method reduced the differ-
ences between patients with and without new CV
events and created a balanced study cohort, such
that healthcare utilization and incremental costs
were more accurately compared.
Conclusion
Substantial incremental costs and healthcare resource
utilization 1 month up to 3 years post-CV event
highlight the short- and long-term economic and clin-
ical burden especially on high-risk hyperlipidemic pa-
tients and the US healthcare system. Interventions
used to prevent or reduce the occurrence of CV
events among patients with hyperlipidemia may result
in substantial cost savings and reduce the clinical
burden in the United States.




Table 6 Cardiovascular risk levels and codes, modified based on NCEP ATP III guidelines
Risk Level Code
History of CV event Myocardial infarction ICD-9-CM: 410, 412
Unstable angina ICD-9-CM: 411.1, 411.81, 411.89
Coronary artery bypass graft CPT-4: 33503-33545
Percutaneous coronary intervention ICD-9 Procedure: 00.66, 36.09
Ischemic Stroke ICD-9 CM: 434, 436, 437.0, 437.1, 438, 997.02
Modified CHD RE Peripheral arterial disease ICD-9-CM: 440.0x-440.4x, 440.8x-440.9x, 443.81, 443.9x
Abdominal aortic aneurysm ICD-9-CM: 441.3x-441.4x
Coronary artery disease ICD-9-CM: 433.1x
Diabetes ICD-9-CM: 249.xx-250.xx
Dyslipidemia ICD-9-CM: 272.0x-272.4x
Moderate risk At least two of the following three risk factors identifiable from
administrative claims data:
a) hypertension (ICD-9-CM code or pharmacy claim for a blood
pressure–lowering agent),
b) age 45 years or older for men and 55 years or older
for womenc) pre-index high-density lipoprotein (HDL)
cholesterol below 40 mg/dl.
Hypertension: ICD-9-CM codes 401.1-401.9, 642.00-642.04, 401.0,
437.2, 402.00-405.99, 642.10-642.24, 642.70-642.94
Low risk Zero or one risk factor
CHD RE coronary heart disease risk equivalent, CV cardiovascular, ICD-9-CM International Classifications of Diseases, 9th Revision Clinical Modifications, CPT Current
Procedural Terminology, NCEPATP III National Cholesterol Education Program Adult Treatment Panel III
Table 5 Cardiovascular event identification codes
Cardiovascular events Diagnosis/Procedure codes
Myocardial Infarction ICD-9-CM: 410.xx
Unstable Angina ICD-9-CM: 411.1x, 411.8x
Ischemic Stroke ICD-9-CM: 433.x1, 434.x1
Coronary Artery Bypass Graft CPT: 33510-33514, 33516-33519, 33521-33523, 33530, 33533-33536
HCPCS: S2205-S2209
ICD-9-CM: 36.10-36.17, 36.19
Percutaneous Coronary Intervention ICD-9-CM: 00.66, 36.06, 36.07, 17.55
CPT: 92980, 92981, 92982, 92984-92996, 92973
HCPCS: G0290, G0291
Transient Ischemic Attack ICD-9-CM: 435.0x, 435.1x, 435.8x, 435.9x
Heart Failure ICD-9-CM: 428.xx
CPT Current Procedural Terminology, HCPCS Healthcare Common Procedural Coding System, ICD-9-CM International Classification of Diseases, Ninth Revision,
Clinical Modification
Fox et al. BMC Cardiovascular Disorders  (2016) 16:13 Page 12 of 15
Table 7 12-month Pre-index demographic and clinical characteristics for hyperlipidemic patients with and without new CV events before matching




















































18-24 [0.0 %] [0.0 %] 0.04 2.8 [0.03 %] [0.05 %] 0.0018 1.1 [0.00 %] [0.00 %] N/A 0.0 [0.2 %] [0.2 %] 0.3062 1.1
25-34 [0.1 %] [0.4 %] <0.0001 6.6 [0.3 %] [0.4 %] 0.0002 1.4 [0.00 %] [0.00 %] N/A 0.0 [1.3 %] [1.8 %] 0.0016 3.4
35-54 [6.9 %] [18.4 %] <0.0001 34.8 [19.6 %] [19.6 %] 0.6784 0.2 [11.7 %] [16.7 %] <0.0001 14.3 [41.3 %] [51.1 %] <0.0001 19.8
55-64 [22.1 %] [32.1 %] <0.0001 22.7 [35.7 %] [35.3 %] 0.0122 0.9 [38.0 %] [41.2 %] <0.0001 6.6 [34.7 %] [33.6 %] 0.0327 2.3
≥65 [70.9 %] [49.2 %] <0.0001 45.6 [44.4 %] [44.7 %] 0.1341 0.5 [50.3 %] [42.1 %] <0.0001 16.5 [22.5 %] [13.3 %] <0.0001 24.1
Male [66.6 %] [63.0 %] <00001 7.7 [62.2 %] [61.1 %] <0.0001 2.4 [62.4 %] [65.2 %] <0.0001 5.9 [60.2 %] [66.4 %] <0.0001 0.1
US geographic region
Northeast [39.3 %] [36.0 %] <0.0001 6.8 [35.3 %] [34.9 %] 0.0398 0.7 [33.1 %] [31.0 %] 0.0003 4.5 [35.8 %] [31.4 %] <0.0001 9.4
Midwest [22.1 %] [25.5 %] <0.0001 8.0 [26.2 %] [26.2 %] 0.2635 0.4 [27.2 %] [28.2 %] 0.0671 2.3 [25.0 %] [28.4 %] <0.0001 7.6
South [24.4 %] [26.3 %] <0.0001 4.4 [26.8 %] [27.3 %] 0.0006 1.3 [26.0 %] [28.3 %] <0.0001 5.2 [27.8 %] [30.4 %] <0.0001 5.7




2.72(2.15) 3.30(2.65) <0.0001 24.3 0.99(1.49) 2.10(2.27) <0.0001 57.6 0.53 (1.23) 0.92(1.69) <0.0001 26.6 0.22(0.78) 0.33 (1.05) <0.0001 11.4
Chronic disease score 5.28(4.06) 6.01(4.44) <0.0001 17.0 3.91(3.48) 5.70(4.24) <0.0001 46.2 4.17 (3.04) 4.70(3.40) <0.0001 16.6 1.16(1.94) 1.28 (2.22) <0.0001 5.8
Baseline number of inpatient
visits PPPM
0.19(0.49) 0.39(0.84) <0.0001 28.8 0.04(0.19) 0.18(0.52) <0.0001 36.1 0.03 (0.19) 0.10(0.35) <0.0001 24.3 0.01 (0.07) 0.03 (0.20) <0.0001 15.6
CHD RE coronary heart disease risk equivalent, SD standard deviation, STD standardized difference, CV cardiovascular, CVD cardiovascular disease, PPPM per patient per month
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